Needham Just Issued "Buy" Rating on Boston Scientific Corporation (BSX)

For the current year, analysts are predicting earnings of $1.100 per share according to First Call. This is the consensus number derived from the 17 analyst reports taken into consideration.

The consensus recommendation for Boston Scientific Corporation (NYSE:BSX) is 1.57.

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. Finally, Citigroup Inc. boosted their price objective on shares of Boston Scientific Corporation from $28.00 to $29.00 and gave the company a "buy" rating in a research report on Thursday, October 6th. Analysts have a mean recommendation of 1.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). The company presently has a consensus rating of "Buy" and a consensus target price of $25.75.

According to consensus agreement of 24 analysts Boston Scientific Corporation (NYSE:BSX) will report earnings per share of $0.29 in their quarterly report and it is expected to announce the company's results on 2/2/17 Before Market Open. Shares of Starbucks Corporation (NASDAQ:SBUX) now have an ABR of 1.52.

In looking at where the stock is trading on a technical level, the stock is trading +10.169% away from its 50 day moving average of $22.688. The company reached its 52-Week high of $25.24 on Feb 2, 2017 and 52-Week low of $15.67 on Feb 8, 2016.

In other news, SVP David A. Pierce sold 10,232 shares of the company's stock in a transaction on Monday, January 9th. The shares were sold at an average price of $22.24, for a total value of $137,776.80. Company insiders own 1.31% of the company's stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy A. Pratt sold 6,195 shares of the business's stock in a transaction that occurred on Monday, January 9th. Post opening the session at $24, the shares hit an intraday low of $23.765 and an intraday high of $24.18 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red. Following the completion of the sale, the executive vice president now directly owns 260,430 shares in the company, valued at approximately $5,333,606.40. The disclosure for this sale can be found here. During the same quarter previous year, the company earned $0.26 earnings per share.

Hedge funds have recently added to or reduced their stakes in the stock.

Analysts polled by Thomson Reuters expected the Boston Scientific to earn $ 0.29 per share on revenue of $ 2.16 billion for the fourth quarter.

Boston Scientific Corporation closed its last trading session at $23.96 with the gain of 4.76%. Boston Scientific Corporation P/E (price to earnings) ratio is 440.35 and Forward P/E ratio of 20.08. Bronfman E.L. Rothschild L.P. increased its stake in Boston Scientific Corporation by 1.5% in the third quarter. Following the transaction, the SVP and President, Endoscopy is left with a stake of 227.56 shares, now valued at $5712.

Military Convoy Sporting 'Trump' Flag Was Naval Special Warfare Unit
Putin Tests Trump With Ukraine Escalation